Summit Therapeutics (SMMT) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 304.8% versus a loss of 22.3%. Over five years, SMMT leads with a +241.6% price change compared with -58.1% for SYRE. Summit Therapeutics is the larger company by market cap ($14.03 billion vs $7.91 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SMMT | SYRE |
|---|---|---|
| Share price | $17.59 | $85.69 |
| Market cap | $14.03B | $7.91B |
| 1-day change | +2.45% | +7.25% |
| YTD return | +0.57% | +161.57% |
| 1-year return | -22.34% | +304.77% |
| 5-year return | +241.55% | -58.10% |
| EPS (TTM) | $-1.14 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-1.08B | $-155.20M |
| 52-week high | $29.23 | $110.18 |
| 52-week low | $12.07 | $18.12 |
| Distance from 52-week high | -39.82% | -22.22% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +69.30% | +40.28% |
| Average volume | 5.87M | 1.22M |
| Shares outstanding | 797.75M | 92.29M |
| Employees | 265 | 125 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed SMMT by 327.1 percentage points over the past year.
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Healthcare · Biotechnology · 265 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Healthcare · Biotechnology · 125 employees
SMMT vs SYRE FAQ
Which is bigger, Summit Therapeutics or Spyre Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $14.03B compared with $7.91B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, SMMT or SYRE?
SYRE returned +304.77% over the past 12 months, compared with -22.34% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Summit Therapeutics and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.